Mir Ali, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, California, about this study

Patients should contact their GP or diabetes specialist nurse if they experience: Severe or persistent vomiting that prevents adequate fluid or food intake, as this increases the risk of dehydration and hypoglycaemia Severe abdominal pain , particularly if constant or radiating to the back, which could indicate pancreatitisa rare but serious adverse effect of GLP-1 receptor agonists Sudden pain in the right upper abdomen, fever or jaundice , which may indicate gallbladder problems (cholelithiasis or cholecystitis) Blood in stools or black, tarry stools Unexplained weight loss beyond what is expected from the medication's therapeutic effect Signs of dehydration , including reduced urine output, dizziness, or confusion Persistent diarrhoea lasting more than a few days Symptoms that significantly impair quality of life or prevent adherence to the medication regimen Pancreatitis is a particular concern with semaglutide, though it remains uncommon

Interestingly, these effects were found to not be simply regulated through the control of the levels of insulin (123)
GLP1 or E monotherapies in an obese model of PCOS Since the 10 nmol/kg dose of GLP1/E was at least as effective as higher doses in improving the metabolic profile of PCOS mice, we compared its beneficial effects in terms of body weight, fat mass, glucose tolerance, insulin sensitivity, and other traits vs
It also boosts Type III collagen, which provides flexibility and supports blood vessels and organs
AOD-9604 works through fat metabolism, not appetite suppression like GLP-1 medications